Loading...
Anebulo Pharmaceuticals, Inc.
ANEB•NASDAQ
Healthcare
Biotechnology
$3.19
$-0.05(-1.54%)
Anebulo Pharmaceuticals, Inc. (ANEB) Financial Performance & Income Statement Overview
Review Anebulo Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
29.49%
↑ 29.49%
Net Income Growth
30.09%
↑ 30.09%
Operating Cash Flow Growth
16.44%
↑ 16.44%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-90.11%
↓ 90.11%
ROIC
-60.62%
↓ 60.62%
Anebulo Pharmaceuticals, Inc. (ANEB) Income Statement & Financial Overview
Review Anebulo Pharmaceuticals, Inc.'s (ANEB) income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $1.22M | $1.31M | $467706.00 | $748339.00 |
| SG&A Expenses | $1.37M | $1.10M | $872661.00 | $915912.00 |
| Operating Expenses | $2.59M | $2.41M | $1.34M | $1.66M |
| Total Costs & Expenses | $2.59M | $2.41M | $1.34M | $1.66M |
| Interest Income | $7067.00 | $26006.00 | $50218.00 | $68084.00 |
| Interest Expense | $59696.00 | $59697.00 | $59696.00 | $59696.00 |
| Depreciation & Amortization | $3.00 | $271088.00 | $50098.00 | $1.66M |
| EBITDA | -$2.40M | -$2.14M | -$1.29M | -$1.59M |
| EBITDA Ratio | ||||
| Operating Income | -$2.59M | -$2.41M | -$1.34M | -$1.66M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $125121.00 | $211388.00 | -$9602.00 | $10709.00 |
| Income Before Tax | -$2.46M | -$2.20M | -$1.35M | -$1.65M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$1.66M |
| Net Income | -$2.46M | -$2.20M | -$1.35M | -$1.65M |
| Net Income Ratio | ||||
| EPS | -$0.09 | -$0.08 | -$0.05 | -$0.06 |
| Diluted EPS | -$0.09 | -$0.08 | -$0.05 | -$0.06 |
| Weighted Avg Shares Outstanding | $27.42M | $25.93M | $25.82M | $25.93M |
| Weighted Avg Shares Outstanding (Diluted) | $27.42M | $25.93M | $25.82M | $25.93M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan